Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

229
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
229
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

622
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
622
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

314
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
314
Neural Regulation01:37

Neural Regulation

39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

168
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
168

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficient Decontamination of Organophosphate-Based Pesticides and Nerve Agent Simulants Mediated by N‑Containing Nucleophiles.

ACS omega·2025
Same author

Instantaneous Hydrolysis of Methyl Paraoxon Nerve Agent Simulant Is Catalyzed by Nontoxic Aminoguanidine Imines.

ACS omega·2025
Same author

Oxidative Stress in Health and Disease.

Biomedicines·2023
Same author

Natural Product Co-Metabolism and the Microbiota-Gut-Brain Axis in Age-Related Diseases.

Life (Basel, Switzerland)·2023
Same author

Advanced Glycation End Products in Health and Disease.

Microorganisms·2022
Same author

Polyphenols and Small Phenolic Acids as Cellular Metabolic Regulators.

Current issues in molecular biology·2022

Related Experiment Video

Updated: Jul 30, 2025

Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

38.1K

RAGE Inhibitors in Neurodegenerative Diseases.

V Prakash Reddy1, Puspa Aryal1, Pallavi Soni1

  • 1Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.

Biomedicines
|May 16, 2023
PubMed
Summary

Advanced glycation endproducts (AGEs) and their receptor (RAGE) drive neurological disorders by promoting inflammation and gut dysbiosis. Inhibiting AGE-RAGE interactions offers a therapeutic strategy for diseases like Alzheimer's.

Keywords:
AGEsAlzheimer’s diseaseRAGERAGE antagonistscytokinesglycationoxidative stresssoluble RAGEtraumatic brain injury

More Related Videos

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
10:50

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons

Published on: April 24, 2021

1.1K
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
10:15

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

8.4K

Related Experiment Videos

Last Updated: Jul 30, 2025

Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

38.1K
Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
10:50

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons

Published on: April 24, 2021

1.1K
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
10:15

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

8.4K

Area of Science:

  • Biochemistry and Molecular Biology
  • Neuroscience
  • Immunology

Background:

  • Advanced glycation endproducts (AGEs) form from nonenzymatic sugar reactions and contribute to cell damage.
  • AGEs interact with the Receptor for Advanced Glycation Endproducts (RAGE), triggering inflammatory signaling pathways.
  • This AGE-RAGE axis is implicated in neurological disorders such as Alzheimer's disease (AD), TBI, ALS, and diabetic neuropathy.

Purpose of the Study:

  • To review the role of AGE-RAGE interactions in the pathogenesis of neurological diseases.
  • To explore the connection between AGE-RAGE signaling, gut microbiota imbalance, and neurological disease progression.
  • To discuss therapeutic strategies targeting the AGE-RAGE pathway for neurological conditions.

Main Methods:

  • Literature review of studies on AGEs, RAGE, and neurological diseases.
  • Analysis of the molecular mechanisms linking AGE-RAGE signaling to inflammation and gut dysbiosis.
  • Examination of current therapeutic approaches, including RAGE antagonists.

Main Results:

  • AGE-RAGE interactions activate pro-inflammatory pathways and contribute to neuroinflammation.
  • Gut microbiota alterations and increased intestinal permeability are associated with AGE-RAGE activity.
  • RAGE antagonists, like Azeliragon, show potential in preclinical and clinical studies for AD treatment.

Conclusions:

  • AGE-RAGE interactions are a significant factor in the onset and progression of neurological diseases.
  • Modulating the gut microbiome and inhibiting AGE-RAGE signaling are promising therapeutic avenues.
  • Further development of RAGE antagonists is crucial for effective treatment of AGE-RAGE-related neurological disorders.